Employer-funded health care and labor markets: an insider’s view by Robert S. Galvin & M.D.
Employer-Funded Health Care and Labor 
Markets: An Insider’s View
Robert S. Galvin, M.D.
I am not here to defend employer-sponsored health care but rather to 
give an insider’s view of several important issues related to the role of 
employers in the U.S. health care system. My perspective comes from my 
role over the past 10 years of being responsible for managing the health 
care costs of the General Electric Company (GE). These total about $2.5 
billion annually and increase by a couple of hundred million dollars a 
year. Even for a ﬁrm like GE, that is serious money. The ﬁve issues that 
I will touch upon rarely make it into the literature about the impact of 
employer-funded health beneﬁts on labor markets.
Medical Innovations 
An issue that I think merits more attention is the role of employer-based 
funding in supporting and enabling medical innovations. Although this 
relationship is not explicit, nor part of the original intent of the system, it 
is still the case that the unique funding and controls (or lack thereof) that 
characterize our system allow for unparalleled access to new technol-
ogy. As much as employers are concerned about how much they spend 
on health care and how that impacts other business decisions, such as 
wage increases or the location of new facilities, it is also the case that one 
person’s cost—or one company’s cost—is another company’s revenue. 
Any attack on health care costs engenders ﬁerce resistance because of 
this cost-revenue relationship, and the resistance is intensiﬁed under cir-
cumstances in which a company is itself in the health care space or has 
important customers that are.
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In our employer-based system, we expect the market to control costs 
in a manner that other countries handle by relying on central govern-
ment-directed global budgeting. But as Alain Enthoven, Mark Pauly, and 
others have taught us, the market is particularly imperfect in health care, 
due to both price distortions and information asymmetry. It has been 
hoped that employers, as sponsors of health beneﬁts, might view it to 
be in their interest to try to ameliorate these shortcomings. To the extent 
that we have tried, we have failed. As a result, the strong incentives for 
employees and providers to use more services has led us to our current 
state, in which the high-tech suppliers to the health care industry—phar-
macy, device, and imaging companies—derive about 50 to 60 percent 
of their proﬁts from the United States, despite the fact that our country 
represents only about 5 percent of the world’s population. By way of full 
disclosure, although I do not work for the health care business at GE, 
and, in fact, frequently frustrate them with ventures like the Leapfrog 
Group,1 GE does have a business in the health care technology ﬁeld, and 
it is doing very well.
The Boston health care market provides a good illustration of the ten-
sion between costs and revenues. In the early 1990s, I was head of the 
Massachusetts Business Roundtable Health Care Subcommittee, where 
the number one issue was the high and rapidly accelerating cost of health 
care. The prevailing wisdom then, as now, was that the overabundance of 
expensive tertiary care beds in the Boston market is a major contributor 
to high health costs. You can imagine my surprise when, as a newcomer 
to this area, I found myself at the ﬁrst meeting, chairing a subcommittee 
composed largely of the CEOs of these same academic medical centers 
and their suppliers. However, the experience provided a good education 
concerning the complexity of addressing costs in health care, as it turned 
out that health care was also the economic engine of the metropolitan 
area. Controlling health care costs without adversely impacting employ-
ment and overall economic growth is no easy matter.
Table 5.1, which Jeff Immelt, GE’s CEO, and I put together, summa-
rizes the situation as it plays out at GE. Jeff likes to call this “the perfect 
hedge”: a $15 billion business growing at 10 percent a year alongside a 
corporate health care cost of $2.5 billion, also growing at 10 percent a 
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revenues from health care to “hedge” the several hundred million dollars 
of new spending that he knows he is going to have every year.
Although having employers as directly engaged in health care funding 
as they are is a historical accident, decoupling them will be no accident—it 
will probably take something like the Jaws of Life to pry those two apart. 
Labor Unions 
A second issue that I would like to address has to do with labor unions 
and what I believe is an underestimation of their impact. Although union-
ized workers represent less than 10 percent of the private labor market, 
their inﬂuence extends beyond their numbers, and it does so in at least 
two ways. The ﬁrst way is through their continuing political clout. The 
Medicare Modernization Act (MMA),2 passed a couple of years ago, 
includes a large employer subsidy for companies that continue to offer 
drug beneﬁts for retirees. Though the government had its own reasons 
for the subsidy, namely, to give employers a reason to continue to offer 
retiree beneﬁts, there was a time late in the development of the bill when 
no such subsidy existed. That an employer subsidy ultimately ended up 
in the bill was largely due to the successful lobbying efforts of businesses 
with very large union populations and very, very large retiree health obli-
gations. If you look at the ripple effect of this subsidy on taxpayers, and 
how all employers covering retiree health care are beneﬁting from it, you 
can get a feel for how the impact of unionization is far greater than what 
you would expect from its 10 percent share of the labor market. 
Table 5.1 
GE in Health Care: The Perfect Hedge
Health Care Business Corporate Health Care
$15 Billion in Revenue
Growing at 10% 
 •  Diagnostics
 •  Services
 •  Information  Technology
$2.5 Billion in Cost
Growing at 10% 
  •  Founder of the Leapfrog Group
 •  Fastest-Growing  Expense
 •  Driving  “Consumerism”
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The second unappreciated fact is the amount of time companies spend 
on union avoidance. For the past several years, health care has been   
an issue of some tension between companies and their workforces.   
With increased cost sharing has come unhappier employees, and with 
unhappier employees comes the threat of unionization. To the extent   
that employers would rather not have unionized workforces, the 
time and resources spent on union avoidance subtract from resource   
allocation in areas more germane to the company’s core products or   
services. 
Positive Impact on Employees 
In a health care system that is notoriously unresponsive and difﬁcult 
to navigate, those employees lucky enough to obtain their insurance   
through midsize or large employers generally have a support system 
unknown in countries with more centralized systems. I do not know 
how many people remember the cover of Newsweek from November 
8, 1999, but it showed a very frustrated-looking patient in a hospital 
gown and the headline: “HMO HELL.” Employers know that unhappy   
employees are less productive; so, although managed care was sav-
ing them a lot of money, employers ultimately backed off because of 
this employee unhappiness. At GE, you could walk around any of our 
sites, and it seemed that at least half of the people were on the phone,   
either on hold with their HMOs or standing at the water cooler com-
plaining about the call they had just ﬁnished. So, a major reason for 
the death of managed care was employee unhappiness. I think that you 
can read this phenomenon as evidence that “the market worked.” It   
is unlikely that a government bureaucracy could be this responsive,   
this fast.
Another impact on employees is the fact that employers are begin-
ning to believe in the connection between health and productivity.   
Although the literature is still immature, big-name companies like John-
son & Johnson and Procter & Gamble are starting to invest in health 
promotion. Although I will not go into this phenomenon any further 
today, I suspect that we will see a big increase in interest in this area in 
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Catalyst for System Innovation 
Large employers have been a catalyst for system innovation. Although 
very few companies invest in a health care staff capable of creating these 
innovations, when successful efforts do occur, all employers (and their 
labor forces) beneﬁt. One example of this is seen in the attempts to apply 
industrial quality approaches, like Continuous Quality Improvement or 
Six Sigma to health care. I do not know how many of you have heard of 
the Leapfrog Group (Galvin et al. 2005), but the mission of that group 
is to drive into health care the kind of transparency around product and 
service performance that exists in the majority of markets. In this case, 
it called for the public release of information around clinical hospital 
performance. The Leapfrog Group, which was founded in 2000, now 
comprises 175 companies, and the majority of hospitals publicly disclose 
information about their quality.
The Leapfrog Group started from an experience I had with an employee. 
As a physician working in industry, I get calls from employees looking for 
help with their medical problems. One such call was from an employee 
who needed heart bypass surgery. He said, “I have a surgeon who is in 
my parish who is a nice person, and someone in my neighborhood said 
they had had a really good experience with this surgeon at our local hos-
pital. I have a date scheduled for my surgery. Am I doing the right thing?” 
I looked everywhere that I could think of for information on quality to 
try to help this employee, but I could not ﬁnd the data about which doc-
tors did this procedure the most, or who had the best outcomes. Since I 
am on the Yale faculty, I called a professor of medicine there who I knew 
had a contract to maintain data on clinical performance in Connecticut 
hospitals. I explained the situation to him and asked whether he could 
tell me what the morbidity and mortality data were. His answer was, 
“I have the data, but I can’t tell you. I’ve signed contracts with the state 
medical and hospital associations committing me to silence.” So I said, 
“That’s a tough situation for me, because I’m trying to do the best for 
this employee. I’ll tell you what. If I mention the three hospitals he could 
go to, would you cough once at the best, and twice at the next best?” 
And he did. The employee ended up changing hospitals to the one with 
the best performance; and, when I investigated further, it turned out that 
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the hospital he went to also had lower costs. So, the idea of demanding 
transparency has been driven by the private sector; and, as this initiative 
has taken off, we now see the Centers for Medicare & Medicaid Services 
in lockstep with this approach. 
Future Directions 
My ﬁnal point has to do with the direction that employer-funded health 
care may take in the future. From an insider’s point of view, the enthusiasm 
around high-deductible, or what are called “consumer-directed” plans, is 
palpable, and unlike anything I have seen since the excitement around 
managed care 15 years ago. I think that the piece, “Hello HSA, Goodbye 
HMO,” (Boorady 2004) by one of the two or three most highly respected 
Wall Street health insurance analysts, Charles Boorady, which I have up 
as a slide, makes a persuasive case as to why the time may be right for this 
kind of product. The argument is that HSAs, or health savings accounts, 
are going to be to health care beneﬁts what 401(k)s became on the retire-
ment side, that is, a way of shifting from a deﬁned beneﬁt to a deﬁned 
contribution model, a move that transfers much of the responsibility for 
decision-making from employer to employee. Although there are only a 
couple of million people covered by HSAs today, I think the prediction 
that 30 percent of the market will adopt this kind of product might not 
be too high. Since 160 million people get their insurance through employ-
ers, 30 percent of this number paying the ﬁrst several thousand dollars of 
their health care bill out of pocket would mean a very big transition in 
both the delivery of health beneﬁts and the ﬂow of health dollars. Many 
of the dollars that in today’s model ﬂow from employer to health plan 
will, in the high-deductible model, ﬂow from employee to provider. 
The reason that I think HSAs may take off is because the product 
meets two major needs: ideologically, it appeals to those who believe 
that a rationalized health care system will never exist unless something is 
done about today’s third-party payment and price distortions; and, prac-
tically, it might represent the ﬁrst step in an eventual exit for employers 
from the burdens of administering health beneﬁts in the way that they do 
today. Employers are interested in this kind of exit but they do not want 
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to their competitors. HSAs may offer a way for employers to maintain 
competitive beneﬁts, have better control of their health costs, and spend 
less administrative resources overall. HSAs would make health insurance 
more portable, which in turn would have a positive effect on labor mar-
kets. These plans will also impact providers; at the very least, they are 
likely to drive up the receivables of doctors and hospitals. I know that 
there is much controversy about this type of beneﬁt design, and hopefully 
we can discuss it further. 
Notes
1.  The Leapfrog Group aims to have information about the performance of hos-
pitals and doctors made available to the public.
2. The full name is “The Medicare Prescription Drug, Improvement, and Mod-
ernization Act of 2003.”
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